MicuRx(SH:688373) Zheng Quan Ri Bao·2026-01-20 13:40Core Viewpoint - The company Mengke Pharmaceutical reported a revenue of 104 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 6.58%, attributed to a slight increase in sales volume and revenue [2] Group 1: Financial Performance - The company's revenue for the first three quarters of 2025 reached 1.04 billion yuan, marking a 6.58% increase compared to the same period last year [2] Group 2: Product Development and Clinical Trials - As of mid-2025, the drug Kantizolamine has been adopted in 580 hospitals nationwide, with 180 hospitals having formal access and bulk procurement [2] - The company initiated a Phase II clinical trial in April 2023 for oral Kantizolamine to treat complex skin and soft tissue infections in Chinese subjects aged 6 to 17, which is currently ongoing [2] - Clinical trials for other drugs, including the prodrug MRX-4, the new drug MRX-8 for resistant Gram-negative bacteria, and MRX-5 for non-tuberculous mycobacterial infections, are progressing as planned [2] - The injectable MRX-4 for treating complex skin and soft tissue infections received NDA acceptance in May 2025 [2]